Calidi Biotherapeutics (CLDI) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $3.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | ONCO |
|---|---|---|
| Share price | $1.04 | $0.6106 |
| Market cap | $3.82M | $3.20M |
| 1-day change | -0.13% | -6.61% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-36.47 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $207.00 |
| 52-week low | $0.986 | $0.58 |
| Distance from 52-week high | -96.26% | -99.71% |
| Average volume | 255.53K | 2.96M |
| Shares outstanding | 3.68M | 5.24M |
| Employees | 29 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CLDI vs ONCO FAQ
Which is bigger, Calidi Biotherapeutics or Onconetix?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.82M compared with $3.20M for Onconetix (ONCO).
Are Calidi Biotherapeutics and Onconetix in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Calidi Biotherapeutics and Biotechnology: Pharmaceutical Preparations for Onconetix.